Skip to main content

Johnson & Johnson Creates Trial Drug Bioethics Panel

Johnson & Johnson has appointed a leading bioethicist to head a panel to determine how to handle requests from people who are critically ill and want access to promising drugs before they are approved.

Republish
Lead image for this article

Johnson & Johnson has appointed a leading bioethicist to head a panel to determine how to handle requests from people who are critically ill and want access to promising drugs before they are approved. The move, which may spur similar efforts by other drug companies, comes amid increasingly high-profile social media campaigns by desperate patients. (The New York Times)

Texans need truth. Help us report it.

Independent Texas reporting needs your support. The Texas Tribune delivers fact-based journalism for Texans, by Texans — and our community of members, the readers who donate, make our work possible. Help us bring you and millions of others in-depth news and information. Will you support our nonprofit newsroom with a donation of any amount?

Support independent Texas news

Become a member. Join today.

Choose an amount or learn more about membership.

$20 $25 $50 Other
Donate now

Information about the authors

Christine Ayala’s staff photo

Learn about The Texas Tribune’s policies, including our partnership with The Trust Project to increase transparency in news.

Explore related story topics